Cibus’s Strategic Initiatives and Financial Improvements Drive Buy Rating
Wall Street analyst Amit Dayal from H.C. Wainwright maintained a Buy rating on Cibus with a $25.00 price target. The rating is based on Cibus's strategic initiatives, financial improvements, commercialization of biofragrance products, cost-cutting measures, optimization of gene editing processes, and international expansion efforts. Favorable regulatory developments in the UK and EU and potential catalysts like new partnerships support the positive outlook.
Cibus, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Amit Dayal from H.C. Wainwright maintained a Buy rating on the stock and has a $25.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Amit Dayal has given his Buy rating due to a combination of factors including Cibus’s strategic initiatives and financial improvements. The company has begun the initial commercialization of its fermentation-based biofragrance products, which is expected to generate significant royalty revenues in the future. Additionally, Cibus’s cost-cutting measures have resulted in a noticeable reduction in operating expenses, indicating improved financial management.
Furthermore, Cibus is focusing on optimizing its Trait Machine gene editing processes and advancing its sustainable ingredients programs, which are supported by customer funding. The company’s international expansion efforts, particularly in India, and the favorable regulatory developments in the UK and EU for genomic techniques, present significant growth opportunities. These strategic moves, along with potential catalysts such as delivering initial traits to customers and forming new partnerships, underpin the positive outlook and Buy rating.
